Sandoz pays out $265M to settle part of antitrust lawsuit
Sandoz and its subsidiary Fougera Pharmaceuticals have agreed to shell out $265 million in an antitrust case brought against them in Pennsylvania’s eastern district.
In the 2016 lawsuit, which has been consolidated into multidistrict litigation that includes states, retail stores and the insurance company Humana, the government alleged that Sandoz and other generic drug manufacturers violated antitrust laws by engaging in a “scheme or schemes to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocations [of certain] generic pharmaceutical products.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
